

February 9, 2023
Symbio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

Notice concerning non-operating expenses

Symbio Pharmaceuticals Limited (the “Company”) today announced accrued non-operating income for the fourth quarter of the fiscal year ended December 31, 2022 (from October 1, 2022 to December 31, 2022) as follows:

1. Details of non-operating expenses

The Company recorded a foreign exchange loss of 209,107 thousand yen under non-operating loss for the fourth quarter of the fiscal year ended December 31, 2022 (from October 1, 2022 to December 31, 2022) due to fluctuations in foreign exchange rates. Together with a foreign exchange gain of 345,287 thousand yen recorded for the first nine months of the fiscal year ended December 31, 2022, the Company recorded a net foreign exchange gain of 136,179 thousand yen in the consolidated statements of income for the fiscal year ended December 31, 2022.

2. Future outlook

Regarding the impact of the above non-operating income on the financial results of Company, please refer to the “Summary of Financial Statements for the Fiscal Year Ended December 31, 2022 [Japanese GAAP] (Consolidated)” also announced on February 9, 2023.

[Contact]

Investor Relations

Tel: +81(0)3 5472 1125